此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ear-Vagus Nerve Stimulation and Body Acupuncture for Gut Motility in Elderly ICU Patients

2026年10月1日 更新者:Qian Zhang、The First Affiliated Hospital with Nanjing Medical University

Auricular Vagus Nerve Stimulation Combined With Body Acupuncture for Gut-Brain Axis Modulation and Improved Gastrointestinal Motility in Elderly Critically Ill Patients

This study aims to investigate whether acupuncture, specifically a combination of body acupuncture and ear vagus nerve stimulation (taVNS), can improve gastrointestinal function in critically ill elderly patients in the Intensive Care Unit (ICU). Gastrointestinal motility problems, such as delayed stomach emptying and constipation, are common in elderly ICU patients and can interfere with feeding, increase infection risk, and worsen outcomes. This research will test if adding acupuncture to standard care helps patients tolerate tube feeding (enteral nutrition) faster, reduces the need for intravenous nutrition, and improves overall recovery. Participants will be randomly assigned to one of three groups: standard care alone, standard care plus body acupuncture, or standard care plus both body acupuncture and ear vagus nerve stimulation. The study will compare the time it takes to achieve target feeding goals, changes in gastrointestinal function scores, and other clinical outcomes. This single-center, prospective, randomized controlled trial will enroll 60 elderly patients from the Geriatric ICU of Jiangsu Province Hospital and aims to provide evidence for integrating traditional Chinese medicine into critical care practice.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 及以上 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age ≥ 65 years.
  2. Critically ill patients admitted to the ICU with APACHE II score ≥ 15.
  3. NRS 2002 score ≥ 3 at ICU admission, indicating risk of malnutrition and requiring nutritional support.
  4. Presence of gastrointestinal dysfunction or at risk, with AGI grade I-II.
  5. Condition considered reversible.
  6. Written informed consent obtained from the participant or legal representative before any study procedures.

Exclusion Criteria:

  1. ICU length of stay less than 7 days.
  2. Presence of severe gastrointestinal disease with contraindications to enteral nutrition and inability to receive conventional medications via the enteral route, such as acute gastrointestinal bleeding, mechanical intestinal obstruction, post-abdominal surgery, or abdominal compartment syndrome.
  3. Skin lesions at the acupuncture sites that are not suitable for acupuncture treatment.
  4. Advanced malignancy with significantly shortened life expectancy.
  5. Participation in another clinical trial.
  6. The treating clinician determines that the intervention is not in the patient's best interest.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Standard Care Group

Standard Care Group

Standard ICU care including hemodynamic management, enteral nutrition support per protocol (energy target: 25 kcal/kg ideal body weight/day; protein target: 1.3 g/kg ideal body weight/day), and management of feeding complications such as diarrhea, abdominal distension, and gastric retention. Enteral nutrition is initiated within 24-48 hours of ICU admission.

有源比较器:Body Acupuncture Group

Participants receive standard ICU care plus body acupuncture therapy. Acupuncture is performed daily by a licensed acupuncturist with 10 years of experience. Needles are inserted at acupoints including CV12, CV10, ST36, PC6, and others, retained for 30 minutes per session. The intervention continues from ICU admission until ICU discharge, death, or discontinuation of nutritional support.

Standard ICU care including hemodynamic management, enteral nutrition support per protocol (energy target: 25 kcal/kg ideal body weight/day; protein target: 1.3 g/kg ideal body weight/day), and management of feeding complications such as diarrhea, abdominal distension, and gastric retention. Enteral nutrition is initiated within 24-48 hours of ICU admission.

Acupuncture at body acupoints including CV13 (Shangwan), CV12 (Zhongwan), CV10 (Xiawan), ST21 (Liangmen), ST25 (Tianshu), SP15 (Daheng), CV4 (Guanyuan), CV6 (Qihai), CV7 (Yinjiao), LI4 (Hegu), TE6 (Zhigou), ST36 (Zusanli), ST37 (Shangjuxu), ST41 (Jiexi), and LR3 (Taichong). Sterile disposable needles (0.25mm × 40mm) are inserted 1-1.5 cun to achieve deqi sensation, retained for 30 minutes per session, once daily.

实验性的:Combined Auricular VNS and Body Acupuncture Group

Participants receive standard ICU care, body acupuncture (as described in Arm 2), and additional transcutaneous auricular vagus nerve stimulation (taVNS). A medium-frequency electrical stimulator is applied to the cymba concha region of the ear (25 Hz, 0-2 mA, 30 minutes per session, once daily). The intervention continues from ICU admission until ICU discharge, death, or discontinuation of nutritional support.

Standard ICU care including hemodynamic management, enteral nutrition support per protocol (energy target: 25 kcal/kg ideal body weight/day; protein target: 1.3 g/kg ideal body weight/day), and management of feeding complications such as diarrhea, abdominal distension, and gastric retention. Enteral nutrition is initiated within 24-48 hours of ICU admission.

Acupuncture at body acupoints including CV13 (Shangwan), CV12 (Zhongwan), CV10 (Xiawan), ST21 (Liangmen), ST25 (Tianshu), SP15 (Daheng), CV4 (Guanyuan), CV6 (Qihai), CV7 (Yinjiao), LI4 (Hegu), TE6 (Zhigou), ST36 (Zusanli), ST37 (Shangjuxu), ST41 (Jiexi), and LR3 (Taichong). Sterile disposable needles (0.25mm × 40mm) are inserted 1-1.5 cun to achieve deqi sensation, retained for 30 minutes per session, once daily.

Medium-frequency electrical stimulator (SNM-FDCM01, Ningbo Maida Medical Instruments Co., Ltd.) applied to the cymba concha region of the ear. Parameters: active period 2 seconds, rest period 3 seconds; pulse width 0.5 ms; frequency 25 Hz; intensity 0-2 mA (maximum tolerable by patient); 30 minutes per session, once daily.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Time to Achieve Enteral Nutrition Target
大体时间:From ICU admission up to 28 days
From ICU admission up to 28 days

次要结果测量

结果测量
措施说明
大体时间
Change in Acute Gastrointestinal Injury (AGI) Grade
大体时间:Baseline Day3 Day 7
Baseline Day3 Day 7
Change in Feeding Intolerance Score (FIS)
大体时间:Baseline Day3 Day 7

Minimum Value: 0 (The lowest score, where all evaluation items are scored as 0).

Maximum Value: 15. The score is calculated by summing three items (abdominal distension and/or pain + nausea and/or vomiting + diarrhea). Since each item has a maximum score of 5, the theoretical maximum total score is 5 + 5 + 5 = 15.

Interpretation (Higher vs. Worse): Higher scores indicate a worse outcome. A higher score represents more severe feeding intolerance (e.g., severe abdominal distension, frequent vomiting, massive diarrhea), requiring stricter clinical management. According to the notes in the image:

0-2 points: Continue enteral nutrition, increase or maintain the original rate, and provide symptomatic treatment.

3-4 points: Continue enteral nutrition, slow down the rate, and reassess after 2 hours.

≥5 points: Suspend enteral nutrition and take corresponding management measures.

Baseline Day3 Day 7
Change in Gastrointestinal Dysfunction Score (GIDS)
大体时间:Baseline Day3 Day 7

Minimum Value: 0 (0 - No risk: No symptoms, or any of the listed conditions present at the time of oral intake).

Maximum Value: 4 (4 - Life-threatening: One of the listed conditions present).

Interpretation (Higher vs. Worse): Higher scores indicate a worse outcome. Higher scores represent more severe gastrointestinal dysfunction and a higher risk of mortality. The specific grades are as follows:

0 (No risk): No symptoms, or any of the following conditions present at the time of oral intake (e.g., absent bowel sounds, vomiting, gastric residual volume >200ml, etc.).

  1. (Increased risk): Two of the following symptoms are present (e.g., no oral intake, absent bowel sounds, vomiting, gastric residual volume >200ml, etc.).
  2. (Gastrointestinal dysfunction): Three or more symptoms scored as 1, OR two of the following symptoms (severe diarrhea, gastrointestinal bleeding requiring transfusion, intra-abdominal pressure >20 mmHg).
  3. (Gastrointestinal failure): Three or more of the followin
Baseline Day3 Day 7
Change in Intra-Abdominal Pressure (IAP)
大体时间:Baseline Day3 Day 7
Baseline Day3 Day 7
Change in Plasma Levels of Intestinal Injury Biomarkers (I-FABP)
大体时间:Baseline Day 7

ng/mL

Baseline Day 7
Change in Plasma Levels of Intestinal Injury Biomarkers (DAO)
大体时间:Baseline and Day 7

ng/mL

Baseline and Day 7
Proportion of Participants Requiring Supplemental Parenteral Nutrition (SPN)
大体时间:Day 7
Day 7
Incidence of Secondary Intestinal Infections
大体时间:Up to 28 days from ICU admission
Up to 28 days from ICU admission
Duration of Mechanical Ventilation
大体时间:Up to 28 days from ICU admission
Up to 28 days from ICU admission
Length of ICU Stay
大体时间:Up to 28 days from ICU admission
Up to 28 days from ICU admission
28-Day Mortality
大体时间:Day 28
Day 28
Change in Plasma Levels of Citrulline
大体时间:Baseline and Day 7

μmol/L

Baseline and Day 7

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年9月20日

首先提交符合 QC 标准的

2026年10月1日

首次发布 (实际的)

2026年10月6日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The de-identified individual participant data (IPD) that underlie the results reported in this article, including data dictionaries, will be made available to researchers who provide a methodologically sound proposal. Data will be available beginning 9 months and ending 36 months following article publication. Proposals should be directed to dongjiaxin1861@163.com. To gain access, data requestors will need to sign a data access agreement.

IPD 共享时间框架

Data will be available beginning 9 months and ending 36 months following article publication.

IPD 共享访问标准

De-identified individual participant data and supporting information will be made available to researchers whose proposed use of the data has been approved by an independent review committee. Requests must be directed to the corresponding author (dongjiaxin1861@163.com) and requestors must sign a data access agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅